Want to see SBFM full AI Analyst Report?
SBFM Stock Chart & Stats
$1.23
$0.01(0.82%)
At close: 4:00 PM EST
$1.23
$0.01(0.82%)
Day’s Range― - ―
52-Week Range$1.80 - $24.30
Previous CloseN/A
Volume1.45K
Average Volume (3M)1.09M
Market Cap
$3.82M
Enterprise Value-$5.11M
Total Cash (Recent Filing)$6.91M
Total Debt (Recent Filing)$744.84K
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Aug 05, 2026EPS Estimate
-1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-87.00
Shares Outstanding2,123,635
10 Day Avg. Volume3,175,467
30 Day Avg. Volume1,091,586
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.14
P/FCF Ratio-0.93
Enterprise Value/Market Cap-1.34
Enterprise Value/Revenue-0.14
Enterprise Value/Gross Profit-0.44
Enterprise Value/Ebitda0.91
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4
Revenue Forecast (FY)$35.39M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low recorded debt and meaningful equity provide structural balance-sheet flexibility. Limited leverage reduces refinancing risk and gives the company room to fund operations or absorb short-term losses without immediate solvency pressure, supporting execution over the next several months.
Stable Gross MarginsConsistent gross margins suggest product-level pricing power and repeatable manufacturing or sourcing economics in its generics and specialty portfolio. That stability supports the potential for operating leverage as revenue recovers, making margin recovery feasible if SG&A is managed.
Improved Liquidity From $6M OfferingThe recent $6M capital raise materially strengthens near-term liquidity and working capital for commercialization and development programs. This provides a clearer runway for execution and product rollouts, reducing immediate funding disruption risk over the next few months.
Bears Say
Persistent Negative Cash FlowConsistent operating and free cash flow deficits indicate structural inability to self-fund operations. Ongoing cash burn forces recurring external financing, heightens dilution risk, and limits capacity to invest in growth or R&D without eroding shareholder value over time.
Sustained Operating LossesDespite revenue scale-up, the company has not reached profitability. Persistent negative EBIT/EBITDA margins show margins after operating costs remain weak, constraining free cash flow generation and making long-term self-sufficiency dependent on margin improvement or continued external capital.
Significant Dilution And Warrant OverhangLarge discounted share issuance and adjustable warrants introduce durable shareholder overhang and potential dilution. This can suppress per-share economics, complicate future capital raises, and signal reliance on equity financing rather than operating cash flow for sustaining growth.
Sunshine Biopharma News
SBFM FAQ
What was Sunshine Biopharma’s price range in the past 12 months?
Sunshine Biopharma lowest stock price was $1.80 and its highest was $24.30 in the past 12 months.
What is Sunshine Biopharma’s market cap?
Sunshine Biopharma’s market cap is $3.82M.
When is Sunshine Biopharma’s upcoming earnings report date?
Sunshine Biopharma’s upcoming earnings report date is Aug 05, 2026 which is in 17 days.
How were Sunshine Biopharma’s earnings last quarter?
Sunshine Biopharma released its earnings results on May 14, 2026. The company reported -$2.5 earnings per share for the quarter, the consensus estimate of -$2.5 by $0.
Is Sunshine Biopharma overvalued?
According to Wall Street analysts Sunshine Biopharma’s price is currently Overvalued.
Does Sunshine Biopharma pay dividends?
Sunshine Biopharma does not currently pay dividends.
What is Sunshine Biopharma’s EPS estimate?
Sunshine Biopharma’s EPS estimate is -1.2.
How many shares outstanding does Sunshine Biopharma have?
Sunshine Biopharma has 2,123,635 shares outstanding.
What happened to Sunshine Biopharma’s price movement after its last earnings report?
Sunshine Biopharma reported an EPS of -$2.5 in its last earnings report, expectations of -$2.5. Following the earnings report the stock price went down -28.905%.
Which hedge fund is a major shareholder of Sunshine Biopharma?
Currently, no hedge funds are holding shares in SBFM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sunshine Biopharma
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Technical Analysis
Sonoma Pharmaceuticals
―
―
cbdMD
―
IM Cannabis Corp
―
Shuttle Pharmaceuticals Holdings, Inc.
―